Morgan Stanley resumed coverage on Organon with a new price target
$OGN
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley resumed coverage of Organon with a rating of Equal-Weight and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | Outperform → In-line | Evercore ISI | |
| 9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
| 11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
| 9/21/2023 | $28.00 | Overweight | Barclays |
| 3/16/2023 | $33.00 | Outperform | Raymond James |
| 10/14/2022 | $27.00 → $25.00 | Neutral → Underperform | BofA Securities |
| 9/6/2022 | $37.00 → $34.00 | Neutral → Overweight | Piper Sandler |
| 8/5/2022 | $40.00 → $37.00 | Buy → Neutral | BofA Securities |
S-8 - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
SD - Organon & Co. (0001821825) (Filer)